Skip to main content
S&P 5007,376.86+0.31%DOW51,285.73-0.46%NASDAQ24,579.42+1.09%BTC$75,946.00-0.25%ETH$2,243.57+0.21%GOLD$4,079.50-0.83%OIL$90.34-0.20%
Smart Investors Daily
SID Premium
AL

NASDAQ · ALKS

Alkermes plc

Healthcare · Biotechnology

$45.90

Up+$1.36 (+3.05%)

Updated Nov 8, 2026, 8:06 PM

SID Score

7.2/10

Composite research score

Smart Money

58/100

Neutral

Market cap
4.97B
P/E ratio
20.51
Dividend yield
0.00%
52-week range
$27.00 – $55.67
Volume
1.67M
Avg. volume
1.92M

Price performance · ALKS

ALKS price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 6, 2026

ALKS closed at $45.90 after 20 trading sessions, up 14.01% for the selected period.

Last close
$45.90
Period change
+14.01%
Period low
$39.08
Period high
$45.90
Daily close
View OHLC price history
ALKS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 6, 2026$44.19$45.94$44.07$45.901.67M
Nov 5, 2026$45.96$46.55$44.415$44.541.94M
Nov 4, 2026$46.23$47.01$44.575$45.892.18M
Nov 3, 2026$46.17$47.43$45.22$45.692.33M
Nov 2, 2026$45.59$45.94$44.485$44.892.16M
Oct 30, 2026$45.67$46.35$44.775$45.341.11M
Oct 29, 2026$46.01$46.38$45.18$45.371.43M
Oct 28, 2026$43.66$45.29$43.45$45.251.44M
Oct 27, 2026$44.34$45.015$43.99$44.321.32M
Oct 26, 2026$44.11$44.84$43.5985$44.441.18M
Oct 23, 2026$44.15$44.15$43.15$43.63884.58K
Oct 22, 2026$44.00$44.69$43.00$44.181.83M
Oct 21, 2026$44.12$44.58$43.44$43.481.81M
Oct 20, 2026$43.38$45.20$43.205$44.112.2M
Oct 19, 2026$41.46$43.64$41.35$42.972.79M
Oct 16, 2026$40.18$41.57$39.71$41.223.41M
Oct 15, 2026$39.74$40.74$39.42$40.101.98M
Oct 14, 2026$39.59$40.65$38.98$39.081.55M
Oct 13, 2026$40.26$40.35$39.67$39.731.07M
Oct 12, 2026$40.67$40.87$40.00$40.262.24M

Latest ALKS news

The latest Smart Investors Daily articles mentioning ALKS.

Stock researchCompany · Overview

ALKS research

Overview

Company profile and research snapshot.

Company profile

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$46.00
Implied upside
—
Analysts
23
ALKS recent ratings
DateFirmRatingTarget
Nov 4, 2026Wells FargoOverweight—
Nov 4, 2026RBC CapitalOutperform—
Nov 4, 2026HC Wainwright & Co.Neutral—
Sep 24, 2026Goldman SachsNeutral—
Sep 22, 2026RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 31, 2026

Alkermes (ALKS) Starts Phase 2 MDD Trial, Is The Upside Already Priced In?

Alkermes (ALKS) has kicked off a phase 2 trial for ALKS 7290 in adults with major depressive disorder, a development that refocuses attention on the stock’s central nervous system pipeline. Investors have already been paying attention to Alkermes, with the share price delivering a 60.44% year to date share price return. The 1 year total shareholder return of 47.69% and 3 year total shareholder return of 85.88% point to strong longer term interest, even though the 90 day share price return...

Yahoo · Oct 30, 2026

Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)

DUBLIN, October 30, 2026--Alkermes plc (Nasdaq: ALKS) today announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants in adult participants with major depressive disorder (MDD). ALKS 7290 is the company’s investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD) and for the adjunctive treatment of MDD.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By